Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies

Annals of Neurology

Volumn 81, Issue 1, 2017, Pages 117-128

  Marquié, Marta ^a   Normandin, Marc D ^a   Meltzer, Avery C ^a   Siao Tick Chong, Michael ^a   Andrea, Nicolas V ^a   Antón Fernández, Alejandro ^a   Klunk, William E ^b   Mathis, Chester A ^b   Ikonomovic, Milos D ^b,c   Debnath, Manik ^b   Bien, Elizabeth A ^a   Vanderburg, Charles R ^a   Costantino, Isabel ^a   Makaretz, Sara ^a   DeVos, Sarah L ^a   Oakley, Derek H ^a   Gomperts, Stephen N ^a   Growdon, John H ^a   Domoto Reilly, Kimiko ^a   Lucente, Diane ^a   Dickerson, Bradford C ^a   Frosch, Matthew P ^a   Hyman, Bradley T ^a   Johnson, Keith A ^a   Gómez Isla, Teresa ^a   more..

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c GERIATRIC RESEARCH EDUCATION AND CLINICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLORTAUCIPIR F 18; NEUROMELANIN; 7-(6-FLUOROPYRIDIN-3-YL)-5H-PYRIDO(4,3-B)INDOLE; CARBOLINE DERIVATIVE; FLUORINE; MAPT PROTEIN, HUMAN; TAU PROTEIN; TRITIUM;

ADULT; AGED; ARTICLE; AUTOPSY; AUTORADIOGRAPHY; BASAL GANGLION; BONE SCINTISCANNING; BRAIN HOMOGENATE; BRAIN REGION; CORRELATIONAL STUDY; DRUG BINDING; ENTORHINAL CORTEX; GRAY MATTER; HUMAN; HUMAN TISSUE; IMAGE RECONSTRUCTION; IMAGING SOFTWARE; MALE; MESENCEPHALON; MIDDLE AGED; NEURITE; NEUROIMAGING; NEUROPATHOLOGY; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIMARY PROGRESSIVE APHASIA; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; TAUOPATHY; WHITE MATTER; BRAIN; CASE REPORT; DIAGNOSTIC IMAGING; FUNCTIONAL NEUROIMAGING; GENETICS; METABOLISM; MUTATION; PATHOLOGY; RADIOASSAY;

AGED; AUTORADIOGRAPHY; BRAIN; CARBOLINES; FLUORINE RADIOISOTOPES; FUNCTIONAL NEUROIMAGING; HUMANS; MALE; MIDDLE AGED; MUTATION; POSITRON-EMISSION TOMOGRAPHY; RADIOLIGAND ASSAY; SUPRANUCLEAR PALSY, PROGRESSIVE; TAU PROTEINS; TAUOPATHIES; TRITIUM;

EID: 85010457809     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24844     Document Type: Article

References (54)

1. Shah M, Catafau AM. Molecular imaging insights into neurodegeneration: focus on tau PET radiotracers. J Nucl Med 2014;55:871–874.
2. Villemagne VL, Fodero-Tavoletti MT, Masters CL, et al. Tau imaging: early progress and future directions. Lancet Neurol 2015;14:114–124.
3. James OG, Doraiswamy PM, Borges-Neto S. PET imaging of tau pathology in Alzheimer's disease and tauopathies. Front Neurol 2015;6:38.
4. Choe YS, Lee KH. PET radioligands for imaging of tau pathology: current status. Nucl Med Mol Imaging 2015;49:251–257.
5. Xia CF, Arteaga J, Chen G, et al. [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement 2013;9:666–676.
6. Johnson KA, Schultz A, Betensky RA, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol 2016;79:110–119.
7. Gordon BA, Friedrichsen K, Brier M, et al. The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. Brain 2016;139(pt 8):2249–2260.
8. Cho H, Choi JY, Hwang MS, et al. Tau PET in Alzheimer disease and mild cognitive impairment. Neurology 2016;87:375–383.
9. Chien DT, Bahri S, Szardenings AK, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis 2013;34:457–468.
10. Brier MR, Gordon B, Friedrichsen K, et al. Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease. Sci Transl Med 2016;8:338ra366.
11. Wang L, Benzinger TL, Su Y, et al. Evaluation of tau imaging in staging Alzheimer disease and revealing interactions between beta-amyloid and tauopathy. JAMA Neurol 2016;73:1070–1077.
12. Scholl M, Lockhart SN, Schonhaut DR, et al. PET imaging of tau deposition in the aging human brain. Neuron 2016;89:971–982.
13. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239–259.
14. Schwarz AJ, Yu P, Miller BB, et al. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain 2016;139(pt 5):1539–1550.
15. Cho H, Choi JY, Hwang MS, et al. In vivo cortical spreading pattern of tau and amyloid in the Alzheimer's disease spectrum. Ann Neurol 2016;80:247–258.
16. Chhatwal JP, Schultz AP, Marshall GA, et al. Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly. Neurology 2016;87:920–926.
17. Whitwell JL, Lowe VJ, Tosakulwong N, et al. [18 F]AV-1451 tau positron emission tomography in progressive supranuclear palsy. Mov Disord 2016 Oct 27. doi: 10.1002/mds.26834. [Epub ahead of print]
18. Hammes J, Bischof GN, Giehl K, et al. Elevated in vivo [18F]-AV-1451 uptake in a patient with progressive supranuclear palsy. Mov Disord 2016 Aug 1. doi: 10.1002/mds.26727. [Epub ahead of print]
19. Cho H, Choi JY, Hwang MS, et al. Subcortical 18 F-AV-1451 binding patterns in progressive supranuclear palsy. Mov Disord 2016 Nov 3. doi: 10.1002/mds.26844. [Epub ahead of print]
20. Mitsis EM, Riggio S, Kostakoglu L, et al. Tauopathy PET and amyloid PET in the diagnosis of chronic traumatic encephalopathies: studies of a retired NFL player and of a man with FTD and a severe head injury. Transl Psychiatry 2014;4:e441.
21. Dickstein DL, Pullman MY, Fernandez C, et al. Cerebral [18 F]T807/AV1451 retention pattern in clinically probable CTE resembles pathognomonic distribution of CTE tauopathy. Transl Psychiatry 2016 Sep 27;6:e900.
22. Smith R, Schain M, Nilsson C, et al. Increased basal ganglia binding of 18 F-AV-1451 in patients with progressive supranuclear palsy. Mov Disord 2016 Oct 6. doi: 10.1002/mds.26813. [Epub ahead of print]
23. Marquie M, Normandin MD, Vanderburg CR, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol 2015;78:787–800.
24. Lowe VJ, Curran G, Fang P, et al. An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun 2016;4:58.
25. Sander K, Lashley T, Gami P, et al. Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias. Alzheimers Dement 2016;12:1116-1124.
26. Hauw JJ, Daniel SE, Dickson D, et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1994;44:2015–2019.
27. Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5’-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998;393:702–705.
28. Dumanchin C, Camuzat A, Campion D, et al. Segregation of a missense mutation in the microtubule-associated protein tau gene with familial frontotemporal dementia and parkinsonism. Hum Mol Genet 1998;7:1825–1829.
29. Becker JA, Hedden T, Carmasin J, et al. Amyloid-beta associated cortical thinning in clinically normal elderly. Ann Neurol 2011;69:1032–1042.
30. Fischl B, Salat DH, van der Kouwe AJ, et al. Sequence-independent segmentation of magnetic resonance images. NeuroImage 2004;23(suppl 1):S69–S84.
31. Logan J, Fowler JS, Volkow ND, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 1990;10:740–747.
32. Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging 2003;2:131–137.
33. Yaghoubi SS, Gambhir SS. PET imaging of herpes simplex virus type 1 thymidine kinase (HSV1-tk) or mutant HSV1-sr39tk reporter gene expression in mice and humans using [18F]FHBG. Nat Protoc 2006;1:3069–3075.
34. Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 2012;8:1–13.
35. Cairns NJ, Bigio EH, Mackenzie IR, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol 2007;114:5–22.
36. McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis 2006;9(3 suppl):417–423.
37. Sanders DW, Kaufman SK, DeVos SL, et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 2014;82:1271–1288.
38. Halfmann R, Lindquist S. Screening for amyloid aggregation by semi-denaturing detergent-agarose gel electrophoresis. J Vis Exp 2008;(17). pii: 838. doi: 10.3791/838.
39. Mesulam M. Primary progressive aphasia: a dementia of the language network. Dement Neuropsychol 2013;7:2–9.
40. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47:1–9.
41. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51:1546–1554.
42. Dickson DW. Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration. J Neurol 1999;246(suppl 2):II6–II15.
43. Kovacs GG, Pittman A, Revesz T, et al. MAPT S305I mutation: implications for argyrophilic grain disease. Acta Neuropathol 2008;116:103–118.
44. Wischik CM, Novak M, Thogersen HC, et al. Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci U S A 1988;85:4506–4510.
45. Tanemura K, Akagi T, Murayama M, et al. Formation of filamentous tau aggregations in transgenic mice expressing V337M human tau. Neurobiol Dis 2001;8:1036–1045.
46. Hong M, Zhukareva V, Vogelsberg-Ragaglia V, et al. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 1998;282:1914–1917.
47. Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013;80:496–503.
48. Gandy S, DeKosky ST. [18F]-T807 tauopathy PET imaging in chronic traumatic encephalopathy. F1000Res 2014;3:229.
49. Gandy S, Ikonomovic MD, Mitsis E, et al. Chronic traumatic encephalopathy: clinical-biomarker correlations and current concepts in pathogenesis. Mol Neurodegener 2014;9:37.
50. Vermeiren C. MJ, Viot D. et al. T807, a reported selective tau tracer, binds with nanomolar affinity to monoamine oxidase a. Alzheimers Dement 2015;11(suppl):P283.
51. Smith R, Puschmann A, Schöll M, et al. 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. Brain 2016;139(pt 9):2372–2379.
52. Josephs KA, Whitwell JL, Tacik P, et al. [18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration. Acta Neuropathol 2016;132:931–933.
53. McMillan CT, Irwin DJ, Nasrallah I, et al. Multimodal evaluation demonstrates in vivo 18F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration. Acta Neuropathol 2016;132:935–937.
54. Reed LA, Grabowski TJ, Schmidt ML, et al. Autosomal dominant dementia with widespread neurofibrillary tangles. Ann Neurol 1997;42:564–572.